KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Other Non Operating Income (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Other Non Operating Income for 8 consecutive years, with -$1.1 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Other Non Operating Income fell 143.68% year-over-year to -$1.1 million, compared with a TTM value of $1.2 million through Sep 2025, down 53.65%, and an annual FY2024 reading of $8.0 million, changed N/A over the prior year.
  • Other Non Operating Income was -$1.1 million for Q2 2025 at Esperion Therapeutics, down from $1.1 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $3.9 million in Q4 2021 and bottomed at -$4.2 million in Q4 2023.
  • Average Other Non Operating Income over 5 years is $786529.4, with a median of $1.1 million recorded in 2025.
  • The sharpest move saw Other Non Operating Income surged 16312.5% in 2021, then crashed 410.77% in 2023.
  • Year by year, Other Non Operating Income stood at $3.9 million in 2021, then crashed by 65.6% to $1.4 million in 2022, then plummeted by 410.77% to -$4.2 million in 2023, then surged by 128.66% to $1.2 million in 2024, then tumbled by 188.82% to -$1.1 million in 2025.
  • Business Quant data shows Other Non Operating Income for ESPR at -$1.1 million in Q2 2025, $1.1 million in Q1 2025, and $1.2 million in Q4 2024.